CRISPR Therapeutics AG (CRSP): who owns it and who trades it
As of Nov 16, 2026, CRSP insiders reported 30 open-market sales worth $17.9M and no purchases in the last 12 months, with 5% of the sale value made under pre-set 10b5-1 plans. The largest seller was Samarth Kulkarni (CEO), with $9.6M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Crispr Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRSP
519 funds and institutions reported CRSP shares worth $4.3B at the end of Q2 2026, about 86% of the company. The largest holder is ARK Investment Management LLC with 9.8%.
Funds and institutions (13F) 86%Everyone else 14%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| ARK Investment Management LLC | 9.46M | 9.81% | $516M | -16% |
| BlackRock, Inc. | 8.35M | 8.66% | $455M | +9% |
| Orbis Allan Gray Ltd | 5.45M | 5.65% | $297M | -11% |
| California State Teachers Retirement System | 5.35M | 5.55% | $98.2M | +5189% |
| Capital World Investors | 4.75M | 4.92% | $259M | +1% |
| State Street Corp | 4.32M | 4.48% | $236M | +9% |
| GSK plc | 3.22M | 3.34% | $176M | No change |
| Geode Capital Management, LLC | 2.51M | 2.60% | $137M | +6% |
| T. Rowe Price Investment Management, Inc. | 2.05M | 2.13% | $112M | -30% |
| SR One Capital Management, LP | 2.04M | 2.11% | $111M | No change |
| Two Sigma Investments, LP | 1.99M | 2.06% | $108M | +34% |
| FMR LLC (Fidelity) | 1.91M | 1.98% | $104M | -2% |
| Sumitomo Mitsui Trust Group, Inc. | 1.72M | 1.78% | $93.8M | -7% |
| Amova Asset Management Americas, Inc. | 1.72M | 1.78% | $93.8M | -7% |
| EcoR1 Capital, LLC | 1.39M | 1.44% | $75.8M | No change |
| UBS Group AG | 1.32M | 1.37% | $71.9M | -25% |
| Capital International Investors | 1.27M | 1.32% | $69.2M | +7% |
| Vanguard Capital Management LLC | 1.18M | 1.23% | $64.5M | +3% |
| Bank of America Corp | 1.16M | 1.20% | $63M | +17% |
| NEA Management Company, LLC | 1.06M | 1.10% | $57.7M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRSP insiders reported $0 of open-market purchases and $17.9M of sales. 5% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Samarth Kulkarni | CEO | Sale | 47,837 | $49.78 | $2.4M | Form 4 |
| Oct 14, 2026 | Simeon George | Director | Sale plan | 14,514 | $49.63 | $720K | Form 4 |
| Oct 14, 2026 | Samarth Kulkarni | CEO | Sale | 4,098 | $49.26 | $202K | Form 4 |
| Oct 14, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 1,040 | $49.26 | $51.2K | Form 4 |
| Oct 6, 2026 | James R. Kasinger | General Counsel and Secr | Sale plan | 1,990 | $60.04 | $119K | Form 4 |
| Sep 22, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 10,400 | $60.24 | $626K | Form 4 |
| Sep 17, 2026 | Ali Behbahani | Director | Sale | 13,679 | $57.09 | $781K | Form 4 |
| May 29, 2026 | Naimish Patel | Chief Medical Officer | Sale | 3,786 | $55.62 | $211K | Form 4 |
| Mar 23, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 3,182 | $46.78 | $149K | Form 4 |
| Mar 23, 2026 | Samarth Kulkarni | CEO | Sale | 10,020 | $46.78 | $469K | Form 4 |
| Mar 23, 2026 | Raju Prasad | CFO | Sale | 3,708 | $46.78 | $173K | Form 4 |
| Mar 16, 2026 | Naimish Patel | Chief Medical Officer | Sale | 3,150 | $48.26 | $152K | Form 4 |
| Mar 16, 2026 | Raju Prasad | CFO | Sale | 5,848 | $48.26 | $282K | Form 4 |
| Mar 16, 2026 | Raju Prasad | CFO | Sale | 4,021 | $48.26 | $194K | Form 4 |
| Mar 16, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 3,450 | $48.26 | $166K | Form 4 |
| Mar 16, 2026 | Samarth Kulkarni | CEO | Sale | 10,349 | $48.26 | $499K | Form 4 |
| Mar 11, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 2,800 | $52.80 | $148K | Form 4 |
| Mar 11, 2026 | Samarth Kulkarni | CEO | Sale | 9,798 | $52.80 | $517K | Form 4 |
| Feb 19, 2026 | Samarth Kulkarni | CEO | Sale | 6,967 | $52.58 | $366K | Form 4 |
| Feb 19, 2026 | James R. Kasinger | General Counsel and Secr | Sale | 2,112 | $52.58 | $111K | Form 4 |
| Jan 22, 2026 | Raju Prasad | CFO | Sale | 34,972 | $60.19 | $2.1M | Form 4 |
| Jan 22, 2026 | Samarth Kulkarni | CEO | Sale | 60,000 | $60.23 | $3.6M | Form 4 |
| Jan 20, 2026 | Samarth Kulkarni | CEO | Sale | 21,433 | $51.61 | $1.1M | Form 4 |
| Jan 20, 2026 | Samarth Kulkarni | CEO | Sale | 8,567 | $52.10 | $446K | Form 4 |
| Jan 6, 2026 | Raju Prasad | CFO | Sale | 5,763 | $60.21 | $347K | Form 4 |
| Jan 6, 2026 | Raju Prasad | CFO | Sale | 5,004 | $60.00 | $300K | Form 4 |
| Jan 6, 2026 | Raju Prasad | CFO | Sale | 18,933 | $60.18 | $1.1M | Form 4 |
| Dec 22, 2025 | Raju Prasad | CFO | Sale | 3,528 | $55.10 | $194K | Form 4 |
| Dec 22, 2025 | Raju Prasad | CFO | Sale | 1,000 | $56.89 | $56.9K | Form 4 |
| Dec 22, 2025 | Raju Prasad | CFO | Sale | 5,472 | $56.33 | $308K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer, Director | – | $9.6M | Oct 19, 2026 |
| Raju Prasad | Chief Financial Officer | – | $5.1M | Mar 23, 2026 |
| James R. Kasinger | General Counsel and Secretary | – | $1.4M | Oct 14, 2026 |
| Ali Behbahani | Director | – | $781K | Sep 17, 2026 |
| Simeon George | Director | – | $720K | Oct 14, 2026 |
| Naimish Patel | Chief Medical Officer | – | $363K | May 29, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRSP short interest
High short interest. 17.7% of CRSP shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 37%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.19M CRSP shares were sold short, 17.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.31M shares, buying them all back would take about 13.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.19M | 17.72% | +5% | 1.31M | 13.1 |
| Oct 15, 2026 | 16.44M | 17.00% | -12% | 1.61M | 10.2 |
| Sep 30, 2026 | 18.68M | 19.32% | -2% | 1.95M | 9.6 |
| Sep 15, 2026 | 19.07M | 19.72% | +2% | 1.15M | 16.5 |
| Aug 31, 2026 | 18.77M | 19.41% | +0% | 1.75M | 10.7 |
| Aug 14, 2026 | 18.74M | 19.39% | -0% | 1.20M | 15.6 |
| Jul 31, 2026 | 18.82M | 19.46% | -5% | 1.63M | 11.5 |
| Jul 15, 2026 | 19.81M | 20.54% | -3% | 1.71M | 11.6 |
| Jun 30, 2026 | 20.40M | 21.15% | -23% | 1.75M | 11.7 |
| Jun 15, 2026 | 26.57M | 27.55% | +23% | 1.63M | 16.4 |
| May 29, 2026 | 21.67M | 22.47% | -21% | 1.76M | 12.3 |
| May 15, 2026 | 27.29M | 28.30% | +21% | 1.65M | 16.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Crispr Therapeutics company events
Crispr Therapeutics filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 19, 2026LeadershipCRISPR Therapeutics AG announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jun 4, 2026LeadershipAt the 2026 Annual General Meeting of Shareholders, the shareholders of CRISPR Therapeutics AG approved the CRISPR Therapeutics AG 2026 Stock Option and Incentive Plan. Filing
- May 4, 2026ResultsReleased financial results. Filing
- Mar 16, 2026AgreementCRISPR Therapeutics AG completed its previously announced private offering of $600.0 million of its Convertible Senior Notes due 2031, including the exercise in full of the initial purchasers’ option to purchase up to an additional $50.0 million principal amount of Notes. Filing
- Mar 11, 2026AnnouncementCRISPR Therapeutics AG issued a press release announcing that it had commenced a private offering, subject to market conditions and other factors, of $350.0 million of convertible senior notes due 2031 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under… Filing
- Feb 12, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementCRISPR Therapeutics AG issued a press release highlighting, among other things, selected updates related to its wholly-owned cardiovascular, autoimmune, immuno-oncology and regenerative medicine programs: • The Company continues to advance a diversified portfolio of in vivo gene editing programs… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Crispr Therapeutics financials
Famous investors that hold CRSP
5 of the 50 well-known investors we track reported holding CRSP in their latest 13F filing. The largest position is Cathie Wood's, worth $556M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 10.06M | $556M | 3.2% | +6% |
| Israel Englander · Millennium Management | Q3 2026 | 91,630 | $5.1M | 0.0% | -76% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 67,302 | $3.7M | 0.0% | -14% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 52,520 | $2.9M | 0.0% | +24% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 4,680 | $259K | 0.0% | -99% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named CRSP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ORBIS INVESTMENT MANAGEMENT LTD | 13G/A | 4.7% |
| Nov 16, 2026 | ORBIS INVESTMENT MANAGEMENT LTD | 13G/A | 4.7% |
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 10.4% |
| Nov 13, 2026 | ARK Investment Management LLC | 13G/A | 10.4% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.2% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.2% |
Questions about CRISPR Therapeutics AG (CRSP) stock
Who owns the most CRSP stock?
The largest reported owner of CRISPR Therapeutics AG (CRSP) is ARK Investment Management LLC, with 9.8% of the company. In total, 519 funds and institutions reported holding CRSP at the end of Q2 2026, together about 86% of the shares. See the largest owners.
Are CRSP insiders buying or selling?
In the last 12 months, CRSP insiders reported no open-market purchases and 30 sales worth $17.9M. The latest trade was on Oct 19, 2026. See every trade.
What is the short interest in CRSP?
As of Oct 30, 2026, 17.19M CRSP shares were sold short, 17.7% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.31M shares, buying them all back would take about 13.1 trading days (days to cover). See the history.
Which famous investors hold CRSP?
5 of the 50 well-known investors we track reported CRSP in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Fisher. The largest position is worth $556M. See all holders.
Executive pay
Crispr Therapeutics's chief executive was paid a total of $7.7M for the year ended Dec 31, 2025, down 77% from $33.2M the year before. In the last 12 months, Crispr Therapeutics's executives and directors bought $49.7K of stock on the open market and sold $17.9M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.